sorafenib accord
accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - agenti antineoplastici - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
sorafenib zentiva 200 mg compresse rivestite con film
helvepharm ag - sorafenibum - compresse rivestite con film - sorafenibum 200 mg ut sorafenibi tosilas 274 mg, hypromellosum, carmellosum natricum conexum, cellulosum microcristallinum, magnesii stearas, natrii laurilsulfas, Überzug: hypromellosum, macrogola, e 171, e 172 (rubrum), pro compresso obducto corresp. natrium 1.75 mg. - carcinoma epatocellulare, carcinoma a cellule renali, schilddrüsenkarzinom - synthetika
sorafenib sandoz
sandoz s.p.a. - sorafenib - sorafenib
sorafenib teva
teva italia s.r.l. - sorafenib - sorafenib
sorafenib medac
medac pharma srl - sorafenib - sorafenib
sorafenib zentiva
zentiva italia s.r.l. - sorafenib - sorafenib
sorafenib mylan
mylan s.p.a. - sorafenib - sorafenib
sorafenib dr. reddys
dr. reddy s s.r.l. - sorafenib - sorafenib
sorafenib eg
eg s.p.a. - sorafenib - sorafenib
nexavar compresse rivestite con film
bayer (schweiz) ag - sorafenibum - compresse rivestite con film - sorafenibum 200 mg per sorafenibi tosilas, cellulosum microcristallinum, carmellosum natricum solo tenuti insieme, hypromellosum, magnesio stearas, natrii laurilsulfas, Überzug: hypromellosum, macrogolum 3350, e 171, e 172 (rosso), per compresso haze corrisp. sodio 0.275 mg. - carcinoma epatocellulare, carcinoma a cellule renali, schilddrüsenkarzinom - synthetika